Drugs / ALTA3263
Trials 1 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT06835569 | Mar 2025 → May 2029 expected | colorectal cancer, non-small cell lung carcinoma, pancreatic ductal adenocarcinoma | Alterome Therapeutics, Inc. | Recruiting | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | ALTA3263 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06835569 ↗ |
| Action | Inhibit | “inhibits multiple mutant forms of KRAS” NCT06835569 ↗ |
| Route | Oral | “Oral ALTA3263 tablets” NCT06835569 ↗ |
| Target | KRAS | “KRAS isoform-selective inhibitor that inhibits multiple mutant forms of KRAS” NCT06835569 ↗ |